Cargando…
Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy
Psoriatic patients with latent tuberculosis infection and properly treated active tuberculosis need careful management when prescribing modern biological drugs. Although data and guidelines regarding tumour necrosis factor-α inhibitors advise caution and initiation of prophylactic therapy in patient...
Autores principales: | MASTORINO, Luca, DAPAVO, Paolo, TRUNFIO, Mattia, AVALLONE, Gianluca, RUBATTO, Marco, CALCAGNO, Andrea, RIBERO, Simone, QUAGLINO, Pietro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Publication of Acta Dermato-Venereologica
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811291/ https://www.ncbi.nlm.nih.gov/pubmed/36065745 http://dx.doi.org/10.2340/actadv.v102.1982 |
Ejemplares similares
-
Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population
por: Mastorino, Luca, et al.
Publicado: (2022) -
Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
por: Mastorino, Luca, et al.
Publicado: (2022) -
Switching from IL23 inhibitors to IL17 inhibitors: A safe and effective practice?
por: Mastorino, Luca, et al.
Publicado: (2022) -
Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
por: Ribero, Simone, et al.
Publicado: (2019) -
Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real‐life study
por: Mastorino, Luca, et al.
Publicado: (2022)